To test the hypothesis that an angiotensin-receptor blocker (ARB), either alone or combined with an ACE inhibitor, is more effective than an ACE inhibitor alone in high-risk patients after MI ...

Effects of varying base-case estimates on the incremental cost–effectiveness ratio of treating all patients with advanced renal insufficiency with an ACE inhibitor versus no ACE inhibitor ...

Inhibition of the renin–angiotensin system using either an angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin-receptor blocker (ARB) effectively decreases rates of urinary protein ...

Routine use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is recommended in proteinuric nontransplant kidney disease patients, to reduce proteinuria and ...

The earlier trial also showed advantages over enalapril on hospitalisation and death rates when patients switched from an ACE inhibitor – enough to get Novartis’ drug included in treatment ...

Researchers continue to investigate ACE inhibitor use in treating liver disease, uterine fibroids, and more. ACE inhibitors ...

The only IV ACE inhibitor is enalapril and it is not commonly used in this manner.